Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: povidone; ascorbyl palmitate; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 13.5 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 4.5 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; ascorbyl palmitate; povidone; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - bimekizumab, quantity: 160 mg/ml - injection - excipient ingredients: polysorbate 80; water for injections; glacial acetic acid; glycine; sodium acetate trihydrate - bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - bimekizumab, quantity: 160 mg/ml - injection - excipient ingredients: glacial acetic acid; polysorbate 80; sodium acetate trihydrate; glycine; water for injections - bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: macrogol 6000; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine -